Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
Henri Gautier OuedraogoAlberto MatteelliGiorgia SulisTegwinde Rebeca CompaoreSerge DiagbougaSimon TiendrebeogoAlberto RoggiKadari CissePier Francesco GiorgettiPaola VillaniLassana SangareJacques SimporeMario RegazziSeni KouandaPublished in: Annals of clinical microbiology and antimicrobials (2020)
In our study, the pharmacokinetic of LPV and RTV was found to be highly variable when coadministrated with RBT 150 mg or 300 mg three times per week. There is a need for specific large study to verify clinical and virological effects of this variation, especially when coadministrated with RBT of 300 mg TPW, and to prevent viral resistance in response to under-dosing of LPV. Trial registration PACTR201310000629390. Registered 28 October 2013, http://www.pactr.org/.